IL33 and hydrops fetalis: Since ventricular remodeling is a key element affecting the prognosis of HF patients, suppression of tumorigenicity 2 (ST2) in humans, which is related to the pathophysiology of ventricular remodeling, has been identified as an important indicator for assessing the prognosis of chronic HF (CHF) patients, and most studies have shown that this substance can act through the IL-33/ST2 pathway in the development and progression of HF [8, 9].